Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.050
-0.100 (-4.65%)
At close: Jun 2, 2026, 4:00 PM EDT
2.080
+0.030 (1.46%)
Pre-market: Jun 3, 2026, 5:17 AM EDT
Allogene Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
152
Market Cap
707.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.00K | -73.00K | -76.84% |
| Dec 31, 2023 | 95.00K | -61.00K | -39.10% |
| Dec 31, 2022 | 156.00K | -113.93M | -99.86% |
| Dec 31, 2021 | 114.09M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Geron | 196.12M |
| CytomX Therapeutics | 35.54M |
| Evommune | 10.00M |
| Omeros | 9.89M |
| Oculis Holding AG | 1.40M |
| Avalo Therapeutics | 59.00K |
ALLO News
- 5 days ago - Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO - TheFly
- 5 days ago - Allogene Therapeutics Announces Planned CEO Succession - GlobeNewsWire
- 5 days ago - Allogene Therapeutics Proxy statement: Proxy filing - Filings
- 7 days ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - Allogene Therapeutics Proxy statement: Proxy filing - Filings
- 17 days ago - Allogene Therapeutics Slides: Corporate presentation - Filings
- 20 days ago - Allogene Therapeutics ends China cell therapy deal with Overland - Reuters
- 20 days ago - Allogene Therapeutics reports Q1 EPS (18c), consensus (18c) - TheFly